Make it stop. For life. in Quebec with a strong IBD community!

Here in Quebec, we are home to a strong community of volunteers, donors and sponsors, as well as an innovative team of researchers and health professionals. These people are the heart and soul of our organization, and there are so many exciting ways to get involved! Every volunteer, donor, researcher and sponsor helps us to improve the lives of those affected by Crohn’s disease and ulcerative colitis, and brings us closer to finding cures.

We welcome newcomers – contact us today and, together, we’ll make it stop. For life.

Regional Director, Québec and Atlantic Provinces

Paul Clément
514-342-0666 ext. 200
1-800-461-4683

Development Coordinator, Montreal​
DC-Mtl@crohnsandcolitis.ca
514-342-0666  ext. 201

Development Coordinator, Quebec​
DC-Qc@crohnsandcolitis.ca​
514-342-0666  ext. 202

Young woman wanting to know more about IBD

Newly Diagnosed Webinar

Do you have questions or want to learn more about living with Crohn's disease and ulcerative colitis? Join us from anywhere you have internet access to learn more about IBD from a nurse ...

 • 
Online Webinar
 • 
Montreal Gala announcement

2019 Montreal Gala

The Montreal Gala for Crohn's and Colitis Canada features a cocktail dînatoire with food provided by some of Montreal’s top restaurants, as well as an auction, and a variety of memorable performances. The evening raises funds for our ground-breaking research projects and critical patient support programs. More details on the Montreal Gala will be revealed soon and tickets will be available to purchase at crohnsandcolitis.ca/montrealgala.

 • 
Grand Quai 200 de la Commune Street West
Montreal, QC
 • 
Remember to bookmark this page.

PROVINCE OF QUEBEC’S OFFICE

1700-2001 Robert-Bourassa Blvd.
Montreal QC H3A 3C6

pclement@crohnsandcolitis.ca (514) 342-0666 1-800-461-4683 (Québec and NB only)

Our Staff
Search by Postal Code

News

Takeda Canada announces positive results for ENTYVIO® (vedolizumab) vs. Humira® (adalimumab) in first IBD study to compare biological agents head-to-head

Takeda Canada announces positive results for ENTYVIO® (vedolizumab) vs. Humira® (adalimumab) in first IBD study to compare biological agents head-to-head

 1 2 3 4 5 6 7 8 9 10